The Section 174 Capitalization Mandate Planning Around an Unfavorable Change

The Bottom Line Up Front

Research-intensive businesses face a transformed tax landscape. Starting in 2022, research and experimental expenditures that companies previously deducted immediately must be capitalized and amortized over five years for domestic research (or fifteen years for foreign research). For companies spending $1 million annually on R&D, this means deducting just $100,000 in year one instead of the full million dramatically increasing taxable income and cash tax payments despite unchanged business operations.

Update: The One Big Beautiful Bill Act signed July 4, 2025 changes everything again. Effective for tax years beginning after December 31, 2024, domestic R&D expenses can once again be immediately deducted. However, foreign R&D costs continue requiring 15-year amortization, and navigating the transition creates complexity that most companies haven't fully addressed.

Why This Matters More Than You Think

When Congress imposed Section 174 capitalization through the Tax Cuts and Jobs Act, most companies underestimated the cash flow impact. The reality proved worse than projections for three reasons:

Cash flow impact exceeds initial models. Companies that modeled steady-state scenarios discovered that reality doesn't cooperate. Research-intensive businesses typically grow R&D spending year over year. When spending increases 20% annually, deductions never catch up to current expenditures—creating permanent cash flow disadvantage that persists even after several years.

Loss companies face acute pain. Companies with net operating losses previously benefited from R&D deductions that increased those losses for future use. Under capitalization (2022-2024), current deductions decreased dramatically. Loss companies generated smaller NOLs while burning cash on R&D, then faced profitable years sooner than expected—often before they were financially ready to sustain positive taxable income.

Estimated tax compliance became critical. Many research-intensive companies significantly underpaid 2022 and 2023 estimated taxes because they didn't fully model Section 174's impact. Underpayment penalties run approximately 8% annually. On six-figure underpayments, penalties alone rival the underlying tax liability.

What the 2025 Legislative Fix Changes (and Doesn't)

The One Big Beautiful Bill Act provides substantial relief, but the rules are more nuanced than "R&D expensing is back":

Domestic R&D gets immediate expensing. For tax years beginning after December 31, 2024, taxpayers can deduct domestic research and experimental expenditures in the year incurred. This permanent change (not a five-year sunset) restores the pre-2022 treatment that companies relied on for decades.

Foreign R&D still requires 15-year amortization. The capitalization requirement for foreign research expenses remains unchanged. Companies with global R&D operations must continue tracking and separately amortizing foreign expenditures over fifteen years.

Retroactive relief for 2022-2024 unamortized costs. Taxpayers can recover unamortized domestic R&D costs from 2022-2024 through accelerated deduction. All taxpayers can deduct remaining balances over one or two years starting in 2025. Small businesses (under $31 million average annual gross receipts) can amend 2022-2024 returns to claim full immediate deductions retroactively.

Software development requires ongoing attention. Software development costs—whether for internal use, customer-facing applications, or commercial products—fall under Section 174 rules. Domestic software development can now be expensed immediately, but foreign software development still requires 15-year amortization.

What Qualifies as Section 174 Expenditure

The statute covers research and experimental expenditures broadly interpreted by IRS guidance:

Common categories requiring attention:

• Employee wages for R&D activities

• Contractor costs for research services

• Supplies consumed in research

• Depreciation on equipment used in research

• Software development costs (all categories)

• Patent application and prosecution costs

• Overhead allocable to R&D activities

What doesn't require capitalization:

• Ordinary testing and quality control inspection

• Efficiency surveys and management studies

• Consumer surveys and market research

• Advertising and promotional activities

• Acquisition of another's patent or completed technology

The distinction between capitalizable R&D and currently deductible business expenses isn't always clear. Companies need documented methodologies for classifying expenditures—a discipline that will prove valuable if IRS examines your classifications during audit.

Planning Strategies That Reduce Impact

Optimize R&D credit claims aggressively. Research credits offset tax liability dollar-for-dollar and remain available under current law. With immediate expensing restored for domestic R&D, the interplay between deductions and credits changes. Companies should reassess R&D credit studies to ensure they're capturing all qualified activities. The value of credits increases when you can also take immediate deductions.

Address the Section 280C election carefully. The interaction between immediate R&D expensing and R&D credits requires attention. Section 280C generally requires reducing deductible R&D expenses by the amount of R&D credits claimed. However, taxpayers can elect to claim a reduced credit (calculated at the corporate rate rather than the full credit rate) to avoid reducing their deduction. This election's value changes with immediate expensing versus amortization.

Separate domestic and foreign R&D meticulously. Since only domestic R&D gets immediate expensing while foreign continues requiring 15-year amortization, tracking the geographic location of research activities matters enormously. Companies with global R&D operations need systems that capture where research activities occur, not just aggregate R&D spending.

Evaluate the small business retroactive amendment opportunity. If your company qualifies as a small business (under $31 million average annual gross receipts) and incurred domestic R&D costs in 2022-2024, amending those returns to claim immediate deductions could generate significant refunds. However, the analysis requires modeling the impact of reduced R&D credits under Section 280C against the benefit of increased deductions.

Consider qualified small business stock planning. For startup and early-stage companies, structuring to qualify for QSBS treatment can eliminate federal tax on up to $10 million of gain (or 10x adjusted basis) upon exit. While this doesn't address immediate cash flow, it provides powerful long-term tax mitigation for companies that built value during years when Section 174 capitalization increased tax burden.

The Software Development Special Case

Software development costs created particular confusion under Section 174 capitalization. Historically, companies treated software development under various provisions—some capitalized under Section 167 or 197 (36-month amortization), others deducted currently under Section 162 or Section 174.

Post-2021 through 2024, software development appeared to mandatorily require five-year amortization under Section 174. Now, with the 2025 changes, domestic software development can be immediately expensed while foreign software development continues requiring 15-year amortization.

Practical implications:

• Internal-use software developed domestically: immediate deduction

• Customer-facing applications developed domestically: immediate deduction

• Software developed by foreign subsidiaries or contractors abroad: 15-year amortization

• Mixed development (domestic and foreign teams): requires allocation and separate treatment

Managing Estimated Tax Compliance Going Forward

The restoration of immediate R&D expensing substantially reduces taxable income for research-intensive companies starting in 2025. This creates new estimated tax challenges:

Safe harbor approaches remain:

• Pay 100% of prior year's tax (110% for certain high-income taxpayers)

• Pay 90% of current year's tax

• Use annualized income method for companies with seasonal or uneven income

The challenge: if you had taxable income in 2024 under Section 174 capitalization but expect much lower income in 2025 with immediate expensing, the prior-year safe harbor may cause significant overpayment. Companies should recalculate quarterly based on year-to-date results.

What You Should Do This Quarter

Model your 2025 tax position under new rules. Calculate what your tax liability looks like with immediate domestic R&D expensing. If you have foreign R&D, ensure you're properly tracking and amortizing those costs separately. Understand your cash tax obligation and ensure estimated payments are appropriate.

Evaluate small business retroactive relief. If you qualify, model whether amending 2022-2024 returns generates sufficient refund to justify the cost and complexity. Consider the timing of refunds, the impact on R&D credits, and whether amended returns might trigger IRS examination.

Document your R&D expense classifications. With immediate expensing available, IRS will scrutinize whether expenses actually constitute qualified R&D versus routine business costs. Build contemporaneous documentation supporting your classifications—the time to prepare for audit questions is during return preparation, not during examination.

Reassess R&D credit positions. With deduction treatment changing, review whether your R&D credit study captures all eligible activities and whether your Section 280C election remains optimal. The math that worked under capitalization may yield different results with immediate expensing.

Review foreign R&D tracking systems. If you have any R&D conducted outside the United States, implement systems that clearly identify foreign versus domestic activities. The differential treatment (immediate expensing versus 15-year amortization) makes this tracking critically important.

The Broader Perspective

Section 174 capitalization represented tax policy working at cross-purposes with innovation policy—providing R&D credits to encourage research while simultaneously requiring capitalization that increased tax on research-intensive businesses. The 2025 legislative fix partially corrects this by restoring immediate domestic R&D expensing.

However, the continuing requirement to capitalize foreign R&D creates complexity and potential traps. Companies must maintain robust systems for tracking research location, distinguishing qualified R&D from routine activities, and optimizing the interplay between deductions and credits.

Let's Model Your Section 174 Impact

Section 174 changes affect every research-intensive business differently based on R&D spending patterns, domestic versus foreign mix, profitability trajectory, and NOL positions. Generic planning doesn't account for your specific situation or opportunities.

JHS USA's tax planning team helps research-intensive companies navigate Section 174 rules, model retroactive amendment opportunities, optimize R&D credit claims, and implement systems that maximize tax benefits while ensuring compliance. We bring both technical depth and practical implementation experience to companies navigating these complex rules.

If you're spending significantly on R&D—whether for product development, software engineering, process improvement, or innovation—let's discuss how the 2025 legislative changes affect your specific situation and what strategies make sense for your business.

About JHS USA Tax Planning Services
JHS USA provides comprehensive tax planning services to businesses across all industries, with particular depth supporting technology companies, life sciences businesses, manufacturing operations, and other research-intensive organizations navigating complex tax requirements.

This article is for informational purposes only and does not constitute tax, legal, or financial advice. Consult with qualified professionals regarding your specific situation.

Copyright © 2025 JHS USA. All rights reserved.